Stock Screener App

Frei -

Installieren

1.90

1.04% -0.02

Engene Therapeutics Inc (ENGN)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten

Layoff Tracker: Novartis cuts New Jersey workforce again, ousting 322 employees - BioSpace

enGene reports 54% response rate in bladder cancer trial - Investing.com

Piper Sandler downgrades enGene Therapeutics (ENGN) - MSN

enGene Therapeutics Inc. Actuals & Estimates (NASDAQ:ENGN) - TradingView

enGene Therapeutics Inc. Financial Disclosures & Filings - TradingView

Enterprise value to EBITDA forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Enterprise value to revenue forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

ENGNenGene Therapeutics Inc Volatility & Greeks - Finviz

Price to earnings forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Enterprise value to EBIT forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

Price to sales forward of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView

enGene Therapeutics Inc. Actuals & Estimates (FWB:S0N0) - TradingView

ENGN Forecast — Price Target — Prediction for 2027 - TradingView

Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGNW - TradingView

EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN

A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo

enGene Therapeutics - The Business Journals

Morgan Stanley Downgrades EnGene to Underweight From Equalweight - Moomoo

ENGN Downgraded by Morgan Stanley -- Rating Changed to Underweig - GuruFocus

EnGene Shares Fall After Morgan Stanley Downgrade - Moomoo

enGene Therapeutics (ENGN) lifts restructuring and retention cost estimates - Stock Titan

enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape - Streetwise Reports

EnGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says - marketscreener.com

Morgan Stanley Downgrades enGene to Underweight From Equalweight - marketscreener.com

Morgan Stanley Downgrades EnGene Therapeutics(ENGN.US) to Sell Rating - Moomoo

Morgan Stanley cuts Engene stock rating on reduced sales outlook - Investing.com

Morgan Stanley cuts Engene stock rating on reduced sales outlook By Investing.com - Investing.com UK

enGene Therapeutics (ENGN) director awarded options for 31,000 shares - Stock Titan

enGene Therapeutics (ENGN) grants director 31,000 stock options - Stock Titan

enGene Therapeutics (ENGN) director receives 31,000 stock options at $1.75 strike - Stock Titan

[Form 4] enGene Therapeutics Inc. Insider Trading Activity - Stock Titan

enGene Therapeutics (ENGN) director awarded 31,000 stock options - Stock Titan

Director Michael Heffernan of enGene (ENGN) awarded options on 31,000 shares - Stock Titan

Lota S. Zoth granted 31,000 options at enGene Therapeutics (ENGN) - Stock Titan

enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV) - The Globe and Mail

Guggenheim Maintains EnGene Therapeutics(ENGN.US) With Hold Rating - Moomoo

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail

EnGene slashes staff by 50% to preserve cash ahead of regulatory push - The Business Journals

ENGN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

enGene Restructures, Cuts Workforce to Advance Bladder Therapy - The Globe and Mail

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com - Investing.com South Africa

H.C. Wainwright cuts Engene stock price target on clinical setbacks - Investing.com

enGene Therapeutics reports Q2 2026 financial results - grafa.com

enGene (ENGN) Announces Workforce Reduction and Leadership Changes - GuruFocus

enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace

enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements – Minichart - Minichart

enGene Therapeutics (ENGN) Q2 2026 earnings summary - Quartr

enGene Reports Q2 2026 Results: 50% Workforce Reduction, BLA Initiation for Detalimogene in 2H 2026, $285M Cash Position, and NMIBC Clinical Updates 12 – Minichart - Minichart

enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary - TradingView

ENGN: Net loss increased, workforce halved, and liquidity remains strong for at least 12 months - TradingView

enGene Therapeutics (ENGN) posts $60M loss, cuts workforce by 50% - Stock Titan

enGene (NASDAQ: ENGN) slashes staff 50% as it advances detalimogene BLA - Stock Titan

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters